IP Library Granted Patent US 9,114,162
Granted Patent B2
US 9,114,162 · App. 11/877,839 · Granted Aug 25, 2015

Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,114,162
App. No.
11/877,839
Granted
Aug 25, 2015
Kind
B2
Abstract

Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Microspheres of the present invention may further be provided with physical and/or chemical enhancements within the particles' cores to enhance visualization of the embolized tissue using a variety of medical imaging modalities, including conventional radiography, fluoroscopy, tomography, computerized tomography, ultrasound, scintillation, magnetic resonance, or other imaging technologies.

Claims (14)

1. A particle for use in a clinical imaging procedure, the particle comprising an inner core and an outer coating, wherein:

the inner core comprises a polymethyl methacrylate hydrolyzed with potassium hydroxide hydrogel and a contrast agent;

the outer coating comprises a poly[bis(trifluoroethoxy)phosphazene] or a derivative thereof.

2. The particle according to claim 1 , wherein the poly[bis(trifluoroethoxy)phosphazene] is poly[bis(2,2,2-trifluoroethoxy)]phosphazene or a derivative of poly[bis(2,2,2-trifluoroethoxy)]-phosphazene.

3. The particle according to claim 1 , wherein the contrast agent is barium sulfate or an iodine-containing agent.

4. The particle according to claim 1 , wherein the contrast agent is selected from Diatrizoate, Metrizoate, Ioxaglate, Iopamidol, Iohexyl, Ioxilan, Iopromide, Iodixanol, Ioxitalamin, or a combination thereof.

5. The particle according to claim 1 , wherein the contrast agent is suitable for ultrasound or computerized ultrasound imaging procedures.

6. The particle according to claim 1 , wherein the hydrogel core contains one or more microbubbles, the microbubbles comprising a gas selected from air, oxygen, carbon dioxide, nitrogen, helium, argon, xenon, or any mixture thereof.

7. The particle according to claim 1 , wherein the contrast agent is suitable for a scintillation imaging procedure.

8. The particle according to claim 7 , wherein the contrast agent is a radioisotope.

9. The particle according to claim 7 , wherein the contrast agent is selected from 67 Ga, 68 Ga, 123 I, 126 I, 131 I, 132 I, 133 I, 111 In, 113 In, 201 Tl, 203 Tl, 3 H, 11 C, 14 C, 13 N, 18 F, 22 Na, 24 Na, 31 Si, 32 P, 35 S, 36 Cl, 38 Cl, 42 K, 45 Ca, 51 Cr, 52 Mn, 54 Mn, 55 Fe, 59 Fe, 60 Co, 63 Zn, 65 Zn, 68 Zn, 82 Br, 85 K, 85 Kr, 89 Sr, 99 Tc, 99m Tc, 99m Re, 105 Re, 105 Re, 121m Te, 122m Te, 125m Re, 137 Cs, 165 Tm, 167 Tm, 168 Tm, 81m Kr, 33 Xe, 90 Y, 3 Bi, 77 Br, 18 F, 95 Ru, 97 Ru, 103 Ru, 105 Ru, 107 Hg, 203 Hg, 182 Ta, 192 Ir, 198 Au, or a combination thereof.

10. The particle according to claim 1 , wherein the contrast agent is suitable for a magnetic resonance imaging procedure.

11. The particle according to claim 10 , wherein the contrast agent is selected from a tantalum compound, a gadolinium compound, a samarium-compound, a paramagnetic rare earth compound, ferric chloride, ferric ammonium citrate, gadolinium-DTPA, gadolinium-DOTA, gadolinium-EDTA, GdCl 3 , Gadodiamide, Gadoteridol, gadopentetate dimeglumine, a Cr(III) compound, a manganese compound, Mn(III)TPPS4 (manganese(III) tetra-[4-sulfanatophenyl]porphyrin), Fe(III)TPPS4 (iron(III) tetra-[4-sulfanatophenyl]porphyrin), manganese dichloride, iron(III) ethylenebis-(2-hydroxyphenylglycine), 99mTc-iminodiacetate, chromium diethyl HIDA meglumine, gadobenate dimeglumine, manganese(II)-dipyridoxal diphosphate, gadolinium oxide, a superparamagnetic iron oxide, a small particle iron oxide, an ultrasmall supermagnetic particle iron oxide, or an ultrasmall particle iron oxide.

12. The particle according to claim 11 , wherein the core further comprises barium sulfate coating the core and/or barium sulfate absorbed within the core.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2020
From: BOSTON SCIENTIFIC CORPORATION
To: VARIAN MEDICAL SYSTEMS, INC.
Reel/Frame 051511/0504 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2016
From: CELONOVA BIOSCIENCES, INC.
To: BOSTON SCIENTIFIC LIMITED
Reel/Frame 038054/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2008
From: BLUEMMEL, JACQUES; KUELLER, ALEXANDER
To: CELONOVA BIOSCIENCES, INC.
Reel/Frame 021850/0688 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2008
From: FRITZ, ULF; FRITZ, OLAF; GORDY, THOMAS A.; WOJCIK, RONALD
To: CELONOVA BIOSCIENCES, INC.
Reel/Frame 020376/0959 →